Tyrosine Kinase Inhibitors Gefitinib, Lapatinib and Sorafenib Induce Rapid Functional Alterations in Breast Cancer Cells

Publisher： Bentham Science Publishers

E-ISSN： 1873-5576|10|4|422-431

ISSN： 1568-0096

Source： Current Cancer Drug Targets, Vol.10, Iss.4, 2010-06, pp. : 422-431

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Polymorphisms to Predict Outcome to the Tyrosine Kinase Inhibitors Gefitinib, Erlotinib, Sorafenib and Sunitinib

By  

Current Topics in Medicinal Chemistry, Vol. 12, Iss. 15, 2012-08 ,pp. : 1649-1659

Bentham Science Publishers

Access to resources Recommend Favorite

Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: in vitro and in cancer patients

By Li Jing   Brahmer Julie   Messersmith Wells   Hidalgo Manuel   Baker Sharyn  

Investigational New Drugs, Vol. 24, Iss. 4, 2006-07 ,pp. : 291-297

Springer Publishing Company

Access to resources Recommend Favorite

Recent Updates on the Therapeutic Potential of HER2 Tyrosine Kinase Inhibitors for the Treatment of Breast Cancer

By  

Current Cancer Drug Targets, Vol. 18, Iss. 4, 2018-04 ,pp. : 306-327

Bentham Science Publishers

Access to resources Recommend Favorite

Emerging tyrosine kinase inhibitors for esophageal cancer

By Ku Geoffrey Y   Ilson David H  

Expert Opinion on Emerging Drugs, Vol. 18, Iss. 2, 2013-06 ,pp. : 219-230

Informa Healthcare

Access to resources Recommend Favorite

Emerging tyrosine kinase inhibitors for head and neck cancer

By Bossi Paolo   Locati Laura   Licitra Lisa  

Expert Opinion on Emerging Drugs, Vol. 18, Iss. 4, 2013-12 ,pp. : 445-459

Informa Healthcare

Access to resources Recommend Favorite